The burden of invasive pneumococcal disease in children with underlying risk factors in North America and Europe

International Journal of Clinical Practice

Volumn 68, Issue 1, 2014, Pages 8-19

  Rose, M A ^a   Christopoulou, D ^b   Myint, T T H ^c   De Schutter, I ^d  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c PFIZER INC   (United States)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

7 VALENT PNEUMOCOCCAL CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; ASPLENIA; BACTEREMIA; CELIAC DISEASE; CEREBRAL PALSY; CHILD; CHRONIC KIDNEY DISEASE; CHRONIC LIVER DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; CONGENITAL MALFORMATION; DIABETES MELLITUS; EUROPE; GASTROINTESTINAL DISEASE; GENETIC DISORDER; GRAFT RECIPIENT; HEART DISEASE; HEMATOLOGIC MALIGNANCY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROCEPHALUS; IMMUNE DEFICIENCY; IMMUNIZATION; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INFECTION RISK; MENINGITIS; MORBIDITY; NEOPLASM; NORTH AMERICA; PNEUMOCOCCAL INFECTION; PREMATURITY; PRIORITY JOURNAL; RISK FACTOR; SICKLE CELL ANEMIA; SYSTEMATIC REVIEW; ADOLESCENT; ADVERSE EFFECTS; CHRONIC DISEASE; COST OF ILLNESS; HIV INFECTIONS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MENINGITIS, PNEUMOCOCCAL; NEWBORN; OPPORTUNISTIC INFECTIONS; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD;

ADOLESCENT; BACTEREMIA; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; COST OF ILLNESS; EUROPE; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; INCIDENCE; INFANT; INFANT, NEWBORN; MENINGITIS, PNEUMOCOCCAL; NORTH AMERICA; OPPORTUNISTIC INFECTIONS; PNEUMOCOCCAL INFECTIONS; RISK FACTORS;

EID: 84890510143     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12234     Document Type: Article

References (62)

1. O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374: 893-902.
2. World Health Organisation. Pneumococcal vaccines. WHO position paper-2012. Wkly Epidemiol Rec 2012; 87: 129-44.
3. De Carvalho Gomes H, Muscat M, Monnet DL, Giesecke J, Lopalco PL., Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001-2007. Euro Surveill. 2009; 14. pii: 19159.
4. McClure CA, Ford MW, Wilson JB, Aramini JJ,. Pneumococcal conjugate vaccination in Canadian infants and children younger than five years of age: recommendations and expected benefits. Can J Infect Dis Med Microbiol 2006; 17: 19-26.
5. Nuorti JP, Whitney CG,. Prevention of pneumococcal disease among infants and children-use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59: 1-18.
6. Desai S, McGeer A, Quach-Thanh C, Elliott D., An advisory committee statement, National Advisory Committee on Immunization (NACI): update on the use of conjugate pneumococcal vaccines in childhood. Canadian Communicable Disease Report 2010. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/10vol36/acs-12/acs- 12-eng.pdf(accessed April 2013)
7. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-46.
8. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006; 295: 1668-74.
9. Gladstone RA, Jefferies JM, Faust SN, Clarke SC,. Continued control of pneumococcal disease in the UK-the impact of vaccination. J Med Microbiol 2011; 60: 1-8.
10. Isaacman DJ, McIntosh ED, Reinert RR,. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 2010; 14: e197-209.
11. Hanquet G, Lernout T, Vergison A, et al. Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges. Vaccine 2011; 29: 2856-64.
12. GlaxoSmithKline UK. Synflorix Suspension for Injection in Pre-filled Syringe. Uxbridge: GlaxoSmithKline Biologicals SA, 2012.
13. Pfizer Limited. Prevenar 13 Suspension for Injection. Sandwich: Pfizer Limited, 2012.
14. European Medicines Agency. Prevenar 13. http://www ema europa eu/ema/index jsp?curl=pages/medicines/human/medicines/001104/smops/Positive/ human-smop-000452 jsp&mid=WC0b01ac058001d127 2012 (accessed February 2013)
15. Sanofi Pasteur MSD Limited. Pneumovax II. Maidenhead: Sanofi Pasteur MSD Limited, 2011.
16. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). Pediatrics 2010; 126: 186-90.
17. National Immunisation Advisory Committee. Pneumococcal infection. Immunisation Guidelines for Ireland. Dublin: Royal College of Physicians Ireland, 2010.
18. Saxon State Ministry for Social Affairs and Consumer Protection. Empfehlungen der Sächsischen Impfkommission zur Durchführung von Schutzimpfungen im Freistaat Sachsen. Dresden: Saxon State Ministry for Social Affairs and Consumer Protection, 2012.
19. Conseil Supérieur de la Santé. Enfants à risque accru d'infections invasives à pneumocoques. Guide de Vaccination. Brussels: Conseil Supérieur de la Santé, 2013.
20. Rozenbaum MH, van Hoek AJ, Fleming D, Trotter CL, Miller E, Edmunds WJ,. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ 2012; 345: e6879.
21. Rozenbaum MH, van Hoek AJ, Fleming D, Trotter CL, Miller E, Edmunds WJ,. Correction to Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ 2012; 345: e7437.
22. van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012; 65: 17-24.
23. Thomas HJ, Wotton CJ, Yeates D, Ahmad T, Jewell DP, Goldacre MJ,. Pneumococcal infection in patients with coeliac disease. Eur J Gastroenterol Hepatol 2008; 20: 624-8.
24. Steenhoff AP, Wood SM, Rutstein RM, Wahl A, McGowan KL, Shah SS,. Invasive pneumococcal disease among human immunodeficiency virus-infected children, 1989-2006. Pediatr Infect Dis J 2008; 27: 886-91.
25. Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics 2008; 121: 562-9.
26. Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2007; 44: 1428-33.
27. Poehling KA, Light LS, Rhodes M, et al. Sickle cell trait, hemoglobin C trait, and invasive pneumococcal disease. Epidemiology 2010; 21: 340-6.
28. Tran L, Hebert D, Dipchand A, Fecteau A, Richardson S, Allen U,. Invasive pneumococcal disease in pediatric organ transplant recipients: a high-risk population. Pediatr Transplant 2005; 9: 183-6.
29. Melegaro A, Edmunds WJ, Pebody R, Miller E, George R,. The current burden of pneumococcal disease in England and Wales. J Infect 2006; 52: 37-48.
30. Biernath KR, Reefhuis J, Whitney CG, et al. Bacterial meningitis among children with cochlear implants beyond 24 months after implantation. Pediatrics 2006; 117: 284-9.
31. Wilson-Clark SD, Squires S, Deeks S,. Bacterial meningitis among cochlear implant recipients-Canada, 2002. MMWR Morb Mortal Wkly Rep 2006; 55 (Suppl 1): 20-4.
32. Hjuler T, Wohlfahrt J, Staum KM, Koch A, Biggar RJ, Melbye M,. Risks of invasive pneumococcal disease in children with underlying chronic diseases. Pediatrics 2008; 122: e26-32.
33. Pilishvili T, Zell ER, Farley MM, et al. Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use. Pediatrics 2010; 126: e9-17.
34. Meisel R, Toschke AM, Heiligensetzer C, Dilloo D, Laws HJ, von Kries R,. Increased risk for invasive pneumococcal diseases in children with acute lymphoblastic leukaemia. Br J Haematol 2007; 137: 457-60.
35. Talbot TR, Hartert TV, Mitchel E, et al. Asthma as a risk factor for invasive pneumococcal disease. N Engl J Med 2005; 352: 2082-90.
36. Ludvigsson JF, Olen O, Bell M, Ekbom A, Montgomery SM,. Coeliac disease and risk of sepsis. Gut 2008; 57: 1074-80.
37. Hjuler T, Wohlfahrt J, Simonsen J, et al. Perinatal and crowding-related risk factors for invasive pneumococcal disease in infants and young children: a population-based case-control study. Clin Infect Dis 2007; 44: 1051-6.
38. Haddad MB, Porucznik CA, Joyce KE, et al. Risk factors for pediatric invasive pneumococcal disease in the Intermountain West, 1996-2002. Ann Epidemiol 2008; 18: 139-46.
39. Hsu KK, Shea KM, Stevenson AE, Pelton SI,. Underlying conditions in children with invasive pneumococcal disease in the conjugate vaccine era. Pediatr Infect Dis J 2011; 30: 251-3.
40. Bruce MG, Deeks SL, Zulz T, et al. International Circumpolar Surveillance System for invasive pneumococcal disease, 1999-2005. Emerg Infect Dis 2008; 14: 25-33.
41. Hennessy TW, Singleton RJ, Bulkow LR, et al. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity. Vaccine 2005; 23: 5464-73.
42. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007; 297: 1784-92.
43. Singleton RJ, Holman RC, Wenger J, et al. Trends in hospitalization for empyema in Alaska Native children younger than 10 years of age. Pediatr Infect Dis J 2011; 30: 528-30.
44. Wenger JD, Zulz T, Bruden D, et al. Invasive pneumococcal disease in Alaskan children: impact of the seven-valent pneumococcal conjugate vaccine and the role of water supply. Pediatr Infect Dis J 2010; 29: 251-6.
45. Lacapa R, Bliss SJ, Larzelere-Hinton F, et al. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine. Clin Infect Dis 2008; 47: 476-84.
46. Millar EV, Pimenta FC, Roundtree A, et al. Pre- and post-conjugate vaccine epidemiology of pneumococcal serotype 6C invasive disease and carriage within Navajo and White Mountain Apache communities. Clin Infect Dis 2010; 51: 1258-65.
47. Weatherholtz R, Millar EV, Moulton LH, et al. Invasive pneumococcal disease a decade after pneumococcal conjugate vaccine use in an American Indian population at high risk for disease. Clin Infect Dis 2010; 50: 1238-46.
48. Hsu K, Pelton S, Karumuri S, Heisey-Grove D, Klein J,. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr Infect Dis J 2005; 24: 17-23.
49. Hsu KK, Shea KM, Stevenson AE, Pelton SI,. Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007. Pediatr Infect Dis J 2010; 29: 289-93.
50. Garcia-Vidal C, Ardanuy C, Gudiol C, et al. Clinical and microbiological epidemiology of Streptococcus pneumoniae bacteremia in cancer patients. J Infect 2012; 65: 621-7.
51. Pessach I, Walter J, Notarangelo LD,. Recent advances in primary immunodeficiencies: identification of novel genetic defects and unanticipated phenotypes. Pediatr Res 2009; 65: 3R-12.
52. Wotton CJ, Goldacre MJ,. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health 2012; 66: 1177-81.
53. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201: 32-41.
54. Tan TQ,. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev 2012; 25: 409-19.
55. van Hoek AJ, Andrews N, Waight PA, George R, Miller E,. Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PLoS ONE 2012; 7: e39150.
56. Byington CL, Korgenski K, Daly J, Ampofo K, Pavia A, Mason EO,. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr Infect Dis J 2006; 25: 250-4.
57. Shouval DS, Greenberg D, Givon-Lavi N, Porat N, Dagan R,. Site-specific disease potential of individual Streptococcus pneumoniae serotypes in pediatric invasive disease, acute otitis media and acute conjunctivitis. Pediatr Infect Dis J 2006; 25: 602-7.
58. Ruckinger S, von KR, Siedler A, van der LM,. Association of serotype of Streptococcus pneumoniae with risk of severe and fatal outcome. Pediatr Infect Dis J 2009; 28: 118-22.
59. European Antimicrobial Resistance Surveillance System. EARSS Annual Report. Bilthoven: EARSS, 2008.
60. Giannattasio A, Squeglia V, Lo Vecchio A, et al. Pneumococcal and influenza vaccination rates and their determinants in children with chronic medical conditions. Ital J Pediatr 2010; 36: 28.
61. Shankar A, Samraj R, Aiyedun V, Janda M, Ramaiah S,. General practitioners' perceptions on pneumococcal vaccination for children in United Kingdom. Hum Vaccin 2009; 5: 177-80.
62. Badertscher N, Morell S, Rosemann T, Tandjung R,. General practitioners' experiences, attitudes, and opinions regarding the pneumococcal vaccination for adults: a qualitative study. Int J Gen Med 2012; 5: 967-74.